0001140361-23-023068.txt : 20230505 0001140361-23-023068.hdr.sgml : 20230505 20230505063035 ACCESSION NUMBER: 0001140361-23-023068 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230502 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eterna Therapeutics Inc. CENTRAL INDEX KEY: 0000748592 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 311103425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11460 FILM NUMBER: 23891120 BUSINESS ADDRESS: STREET 1: 1035 CAMBRIDGE STREET STREET 2: SUITE 18A CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: (212) 582-1199 MAIL ADDRESS: STREET 1: 10531 4S COMMONS DRIVE STREET 2: SUITE 166-550 CITY: SAN DIEGO STATE: CA ZIP: 92127 FORMER COMPANY: FORMER CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc. DATE OF NAME CHANGE: 20210325 FORMER COMPANY: FORMER CONFORMED NAME: NTN BUZZTIME INC DATE OF NAME CHANGE: 20051230 FORMER COMPANY: FORMER CONFORMED NAME: NTN COMMUNICATIONS INC DATE OF NAME CHANGE: 19920703 8-K 1 brhc20052521_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 2, 2023

Eterna Therapeutics Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-11460
31-1103425
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1035 Cambridge Street, Suite 18A

Cambridge, MA
02141
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number, including area code: (212) 582-1199

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading symbol
Name of each exchange on which registered
Common Stock, par value $0.005 per share
ERNA
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Principal Financial Officer

On May 4, 2023, the Board of Directors of Eterna Therapeutics Inc., a Delaware corporation (the “Company”), appointed Sandra Gurrola, the Company’s current Vice President, Finance (and principal accounting officer), as the Company’s principal financial officer, which appointment became effective on May 5, 2023.
 
Ms. Gurrola has served as the Company’s Vice President of Finance since June 2021. Prior to that, she served as the Senior Vice President of eGames.com Holdings, LLC from March 2021 to June 2021 and as a consultant to us. Ms. Gurrola served as Senior Vice President of Finance to NTN Buzztime, Inc. from September 2019 to March 2021 and its Vice President of Finance from 2014 until 2019. From 2009 to 2014, Ms. Gurrola served NTN Buzztime, Inc. in various leadership accounting roles, including Controller, Director of Accounting, and Director of Financial Reporting and Compliance. Previously, she was a senior manager of financial reporting for Metabasis Therapeutics, Inc., a biotechnology company. Ms. Gurrola received a B.A. in English from San Diego State University.
 
Since the beginning of the Company’s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which Ms. Gurrola was or is to be a participant and in which Ms. Gurrola had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000, other than with respect to Ms. Gurrola’s compensation arrangements, all of which the Company has previously reported.
 
Separation of Andrew Jackson

On May 2, 2023, the Company entered into a Separation Agreement and General Release (the “Separation Agreement”) with Mr. Andrew Jackson, the Company’s Chief Financial Officer, pursuant to which Mr. Jackson resigned from his position as Chief Financial Officer (principal financial officer) and as an officer, director, manager or employee of the Company’s subsidiaries. Mr. Jackson’s resignation became effective on May 4, 2023 (the “Separation Date”).  In consideration for Mr. Jackson’s execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Mr. Jackson will be entitled to the following benefits under the Separation Agreement:


 •
payment of Mr. Jackson’s annual base salary for a period of six (6) months after the expiration of the applicable revocation period (the “Separation Period”), for a total gross amount equal to $207,500; and


•
payment of Mr. Jackson’s premiums for continued health benefits provided under COBRA for the Separation Period.

Pursuant to the Separation Agreement, all 33,239 unvested options granted to Mr. Jackson were immediately forfeited as of the Separation Date. Under the Separation Agreement, Mr. Jackson has agreed to cooperate with and assist the Company regarding certain matters and transitioning his employment duties and responsibilities. Subject to certain exceptions and limitations, the Separation Agreement includes a general release of claims by Mr. Jackson in favor of the Company and certain related persons and parties, and customary confidentiality and mutual non-disparagement provisions. The Separation Agreement also includes certain other customary representations, warranties and covenants of Mr. Jackson, and provides for reimbursement of certain expenses incurred by Mr. Jackson. The Separation Agreement supersedes all other agreements or arrangements between Mr. Jackson and the Company regarding the subject matter of the agreement, including those with respect to severance payments and benefits.
 
The foregoing description of the Separation Agreement is only a summary and is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.02.
 
Item 9.01
Financial Statements and Exhibits.
 
Exhibit
Number
Description

Separation Agreement and General Release, dated May 2, 2023, by and between Eterna Therapeutics Inc. and Andrew Jackson.
     
104
Cover Page Interactive Data File (embedded within the XBRL document)

**
Management contract or compensation plan or arrangement.
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Eterna Therapeutics Inc.


Dated: May 5, 2023
By:
/s/ Matthew Angel


Chief Executive Officer and President


EX-10.1 2 brhc20052521_ex10-1.htm EXHIBIT 10.1
Exhibit 10.1

Eterna Therapeutics Inc.
10355 Science Center Drive, Suite 150
San Diego, CA 92121
 
May 2, 2023
 
Andrew Jackson
Via email
 
 
RE:
Separation Agreement and General Release
 
Dear Andrew:
 
The purpose of this separation agreement (the “Separation Agreement”) is to memorialize the terms and conditions of your voluntary resignation from employment with Eterna Therapeutics Inc. (the “Company”) and its subsidiaries and affiliates (together with the Company collectively, the “Company Group”), as well as the termination of that certain Amended and Restated Executive Employment Agreement, dated May 10, 2022, by and between YOU (the terms “YOU” and “YOUR” refer to Andrew Jackson) and the Company (for clarity, as referenced in the Employment Agreement, the Company is formerly known as Brooklyn ImmunoTherapeutics, Inc.) (the “Employment Agreement”). The Company accepts YOUR voluntary resignation and agrees to report your resignation as a voluntary resignation on the applicable Form 8-K.  Capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Employment Agreement.
 
To ensure that YOUR resignation from the Company occurs on mutually acceptable terms, this Separation Agreement, along with the General Release of Claims on Exhibit A, attached hereto and made a part hereof (the “General Release”), contains the binding terms and conditions with respect to YOUR resignation including, without limitation, the compensation, and benefits that will be provided to YOU by the Company.
 
Separation Date
 
The effective date of the resignation of YOUR employment with the Company, and the termination of the Employment Agreement, is May 4, 2023 (“Separation Date”).
 
Resignation as Officer and Director of the Company Group
 
YOU acknowledge and agree that, effective as of the Separation Date, YOU will be deemed to have resigned from all positions then held as an officer as well as a member of any board of directors or managers (or any similar governing body), and any committee thereto, throughout the Company Group.
 
Accrued Obligations
 
Whether or not YOU choose to sign this Separation Agreement and the General Release, the Company will pay to YOU any (a) accrued but unpaid base salary YOU have earned through the Separation Date, (b) accrued but unused paid time off through the Separation Date (c) reimbursement for unreimbursed business expenses properly incurred by YOU pursuant to the Company’s applicable expense reimbursement policy; and (d) any accrued but unpaid benefits provided under the Company’s employee benefit plans, subject to and in accordance with the terms of those plans, in each case, less applicable withholding and employment taxes, all of which shall be paid to YOU by the Separation Date or such other date as required under the applicable employee benefit plan.
 
For purposes of this Separation Agreement and the General Release, the amounts described above in this section shall be referred to as the “Accrued Obligations”.
 
Separation Benefits
 
In the event that YOU execute and deliver to the Company both the Separation Agreement and the General Release, and YOU do not revoke the General Release within the Revocation Period (as defined below), the following shall apply (subject to any timing restrictions as may be applicable under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)):
 

 •
Commencing on the first regular payroll date immediately following the end of the Revocation Period, the Company shall continue to pay to YOU YOUR annual base salary for a period of six (6) months thereafter (the “Severance Period”) in accordance with the Company’s normal payroll processing, for a total gross amount equal to $207,500 (less applicable income and employment tax withholdings).
 

 •
If YOU (or YOU and YOUR eligible dependents) timely and properly elects health insurance continuation rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company will pay the entire cost of the COBRA premiums until the earlier of (i) the last day of the Severance Period or (ii) the termination of YOUR rights under COBRA; provided, for the avoidance of doubt, that such covered dependents participated in the Company’s health plans prior to such separation, and provided, further, that if at any time the Company determines that its payment of YOUR (or YOUR eligible dependents’) premiums would result in a violation of law, then in lieu of providing the premiums described above, the Company will instead pay YOU a fully taxable monthly cash payment in an amount equal to the applicable premiums for such month, with such monthly payment being made on the last day of each month for the remainder of the Severance Period.
 
For purposes of this Separation Agreement and the General Release, the benefits described above in this section shall be referred to as the “Separation Benefits”. Except for the Accrued Obligations, the payments from the Company to YOU pursuant to the terms of this Separation Agreement (including the Separation Benefits) are not provided as a raise, bonus, or condition of YOUR employment with the Company.
 
2
YOU acknowledge and agree that as of the Separation Date, this Separation Agreement and General Release shall supersede and replace all benefits, rights and obligations in connection with YOUR employment with the Company Group, including under the Employment Agreement (except for those terms in the Employment Agreement that are explicitly restated herein). Accordingly, YOU further acknowledge and agree that this Separation Agreement and the General Release sets forth all compensation and benefits to which YOU are entitled and shall be paid to YOU in full satisfaction thereof, in connection with your employment with the Company Group.
 
YOU also acknowledge and agree that the Separation Benefits to be paid under this Agreement is due solely from the Company and that Insperity PEO Services, L.P. (“Insperity”), the professional employer organization retained by the Company, has no obligation to pay the Severance benefits, even though its payment may be processed through Insperity.
 
Equity Awards
 
YOU acknowledge and agree that as of the Separation Date, one hundred percent (100%) of the stock option grant that was granted to you on June 3, 2022 (which specifically relates to 33,239 shares of the Company) is unvested and shall be immediately forfeited as of the Separation Date.
 
YOU acknowledge and agree that you do not have any rights with respect to any other equity awards or equity-based interests in the Company.
 
Agreement Preparation and Negotiation Fees

Upon submission of invoices and other applicable documentation reasonably requested by the Company, the Company shall reimburse you for reasonable attorneys’ fees and costs incurred by you in connection with your separation including the preparation and negotiation of this Separation Agreement and General Release, up to a maximum amount of $5,000.
 
3
Integration of Employment Agreement; Survival of Certain Provisions
 
As of the Separation Date, YOU acknowledge and agree that this Separation Agreement shall supersede and replace the Employment Agreement (which shall be deemed terminated as of the Effective Date), except for the following provisions that are specifically incorporated by reference herein (collectively, the “Survival Provisions”): Section 6 (Company Property); Section 9 (Protection of Confidential Information); Section 10 (Intellectual Property); Section 11 (Publicity; Non-disparagement), except the parties agree that nothing in this Separation Agreement or the Employment Agreement prevents YOU from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that YOU have reason to believe is unlawful; Section 20 (Dispute Resolution) and Section 21 (Indemnification) which shall remain in full force and effect except the parties agree that (a) individual claims under the Private Attorneys General Act (“PAGA”) can be subject to arbitration under that Section 20 and (b) the following claims are excluded from the scope of that Section 20: (i) claims under the National Labor Relations Act, (ii) those that constitute collective, representative claims under PAGA, unless applicable laws (whether now or in the future) permit such PAGA claims to be subject to arbitration; (iii) claims under the California Workers’ Compensation Act, (iv) claims for unemployment compensation benefits, (v) claims for benefits under a plan that is governed by the Employee Retirement Income Security Act of 1974, (vi) claims that are subject to the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act, or (vii) claims that are expressly prohibited from mandatory arbitration under applicable law. Accordingly, YOU further acknowledge and agree that (i) this Separation Agreement sets forth all compensation and benefits to which YOU are entitled under YOUR Employment Agreement; and (ii) in the event that YOU breach any of the Survival Provisions, the Separation Benefits shall cease immediately and YOU will no longer be entitled to such benefits.
 
Release Of Claims Against The Company Group
 
In exchange for and as a condition to receiving the Separation Benefits, YOU shall knowingly and willingly release the Company Group from any kind of claim YOU have arising out of or related to YOUR employment, the Employment Agreement and/or the termination of YOUR employment with the Company Group by executing the General Release attached hereto as Exhibit A.
 
YOU will be required to execute the General Release, and therefore agree to be bound by the terms and conditions thereof, no earlier than the Separation Date but no later than thirty (30) days after such Separation Date.
 
Cooperation/Assistance; Employment Verification
 
Cooperation and Assistance: Upon reasonable notice and at reasonable times, YOU agree to assist and cooperate with the Company, by telephone or video conference or otherwise, concerning business or legal related matters about which YOU possess relevant knowledge or information. Such cooperation shall only be provided at the Company’s specific request and will include, but not be limited to, assisting or advising the Company with respect to any business-related matters or any actual or threatened legal action (including testifying in depositions, hearings, and/or trials) about which YOU possess relevant knowledge or information. In addition, you agree to promptly inform the Company if any person or entity contacts YOU in an effort to obtain information about the Company. The Company agrees to reimburse YOU for all reasonable and necessary costs and expenses incurred in connection with such cooperation and will compensate YOU at a reasonable rate for time spent by YOU at the Company’s request in connection with such cooperation.
 
Employment Verification:  If requested, the Company agrees to provide a neutral reference for YOU consisting of dates worked and positions held. The Company may confirm YOU voluntarily resigned, but not elaborate on the reasons for the resignation or matters leading up to the separation. YOU agree to refer all such requests for references to the Company, c/o Donna Parkinson, HR Specialist, or any person who assumes the HR Specialist or similar role, should Ms. Parkinson leave the Company.
 
4
Severability; Entire Agreement; No Oral Modifications; No Waivers
 
If a court of competent jurisdiction determines that any of the provisions of this Agreement are invalid or legally unenforceable, all other provisions of this Agreement shall not be affected and are still enforceable. This Separation Agreement and the General Release are intended to be a single integrated contract expressing our entire understanding regarding the subjects it addresses. As such, it supersedes all oral and written agreements, promises, representations and discussions that occurred before the time YOU sign each of them except as to any obligations YOU may owe to the Company Group as described in the “Integration of Employment Agreement; Survival of Certain Provisions” section above that remain in effect and for the avoidance of doubt, no extrinsic evidence may be introduced in any judicial proceeding or arbitration involving this Separation Agreement. This Separation Agreement and the General Release may be amended or modified only by an agreement in writing signed by YOU and countersigned by an executive officer of the Company. The failure by the Company or YOU (i) to declare a breach, or (ii) to otherwise assert rights under this Agreement shall not be construed as a waiver of any of rights under this Separation Agreement and the General Release. This Separation Agreement and the General Release may be executed and delivered (including by facsimile or other electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same instrument.
 
Governing Law; Venue
 
This Separation Agreement and the General Release shall be governed by the laws of the State of California applicable to contracts executed and performed within that State and without respect to conflict of laws principles of such State that would require the application of the laws of any jurisdiction other than those of the State of California. The parties hereto irrevocably and unconditionally (i) agree that any suit, action or legal proceeding arising out of or relating to this Agreement shall be brought in the courts of record of the State of California or the court of the United States, Southern District of California; and (ii) consent to the jurisdiction of each such court in any suit, action or proceeding.
 
Acknowledgements and Certifications
 
YOU acknowledge and certify that:
 

 •
YOU have read and YOU understand all of the terms of this Separation Agreement and the General Release on Exhibit A, and are not relying on any representation or statement, written or oral, not set forth in this Separation Agreement and the General Release;
 

 •
YOU are signing this Separation Agreement, and shall sign the General Release, knowingly and voluntarily;
 

 •
YOU have been advised to consult with an attorney before signing this Separation Agreement and the General Release;
 
5

 •
YOU have the right to consider the terms of this Separation Agreement and the General Release for 21 days; however, YOU do not have to take all 21 days to consider it, and if YOU take fewer than 21 days to review this Separation Agreement and the General Release, YOU expressly waive any and all rights to consider this Separation Agreement and the General Release for the balance of the 21-day review period; and
 

 •
the General Release includes a release of any claim YOU might have under the Age Discrimination in Employment Act (the “ADEA Claims”). For seven (7) days after signing the General Release, YOU have the right to revoke YOUR release of ADEA Claims (the “Revocation Period”). To revoke YOUR release of ADEA Claims, the revocation or rescission must be in writing and must be delivered by hand or sent by certified mail, return receipt requested, postmarked within the seven (7) day period, and properly addressed to the Chairman of the Company at 1035 Cambridge St Ste 18A, Cambridge MA 02141. Revoking YOUR release of ADEA Claims shall result in the invalidation of this Separation Agreement, in its entirety, as of such revocation date; and
 

 •
YOU and the Company each agree that any changes that have been made to this Separation Agreement and the General Release from the versions originally presented to YOU do not extend the 21-day period YOU have been given to consider this Separation Agreement and the General Release, whether those changes are deemed material or non-material.
 
IF YOU SIGN THIS DOCUMENT AND EXHIBIT A ATTACHED HERETO, IT BECOMES A LEGALLY ENFORCEABLE AGREEMENT EFFECTIVE ON THE DATE SIGNED BY THE COMPANY.
 
Dated: May 2, 2023
/s/ Andrew Jackson
  
 
ANDREW JACKSON
   
Dated: May 2, 2023
ETERNA THERAPEUTICS
 
INC.
   
 
By: /s/ Matthew Angel
  
 
Name: Matthew Angel
 
Title:  CEO

6
EXHIBIT A
 
GENERAL RELEASE OF CLAIMS
 
1.          In exchange for the Separation Benefits described in that certain Separation and Release Agreement (the “Company”), dated May 2, 2023 (the “Separation Agreement”) to which this General Release of Claims is attached as Exhibit A thereto, Andrew Jackson (“Executive”), for himself and his family, heirs, executors, administrators, legal representatives and their respective successors and assigns, does hereby release and forever discharge the Company and its subsidiaries, affiliated companies, successors and assigns (together with Company, the “Company Group”) and Insperity PEO Services, L.P., the professional employer organization retained by the Company, and its current and former parent companies, subsidiaries and other affiliates (collectively, “Insperity”), and their respective current or former directors, officers, employees, shareholders, insurers or agents in such capacities (collectively with the Company Group and Insperity, the “Released Parties”) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or in connection with Executive’s employment or termination thereof, and/or in connection with or arising under the Employment Agreement (as defined in the Separation Agreement), whether for tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment. Executive acknowledges that the Company Group encouraged him to consult with an attorney of his choosing, and through this General Release of Claims encourages him to consult with his attorney with respect to possible claims under the Age Discrimination in Employment Act (“ADEA”) and that he understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Executive expressly waives any and all claims under ADEA that he may have as of the date hereof. Executive further understands that by signing this General Release of Claims he is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i) any rights to receive any payments or benefits pursuant to the Separation Agreement, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any indemnification rights Executive may have as a former officer or director of the Company Group, (iv) any claims for benefits under any directors’ and officers’ liability policy maintained by the Company Group in accordance with the terms of such policy, (v) any indemnification rights set forth in the parties’ prior Employment Agreement; and (vi) any rights as a holder of equity securities of the Company. This General Release is not intended to include, and does not affect a release of, claims for: (a) state disability and/or unemployment insurance benefits pursuant to the terms of applicable state law; (b) any benefit entitlements vested as of the date of the Executive’s termination, pursuant to written terms of any employee benefit plan; (c) continued participation in certain group benefit plans on a temporary basis to the extent eligible pursuant to the federal Consolidated Omnibus Budget Reconciliation Act of 1985 (commonly known as COBRA); and (d) any other claims that may not be waived or released pursuant to statute or other applicable law.
 
A-1
2.           Executive represents that he has not filed against the Released Parties any complaints, charges, or lawsuits arising out of his employment or under his Employment Agreement, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that he will never individually or with any person file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Executive pursuant to paragraph 1 hereof (a “Proceeding”); provided, however, that
 
a.          Nothing in this Agreement (i) prohibits or prevents the Executive from filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal, state or local anti-discrimination, anti-harassment, or anti-retaliation laws; and (ii) is intended to or shall infringe upon Employee’s rights under Section 7 of the National Labor Relations Act. However, to the maximum extent permitted by law, the Executive agrees that if such an administrative claim is made to such an anti-discrimination, anti-harassment, or anti-retaliation agency, he shall not be entitled to recover any individual monetary relief or other individual remedies. In addition, nothing in this Agreement, including but not limited to the release of claims and non-disparagement clauses, prohibits the Executive from (A) reporting possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (B) making any other disclosures that are protected under the whistleblower provisions of federal law or regulations; or (C) otherwise fully participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S. Securities and Exchange Commission and\or the Occupational Safety and Health Administration. Moreover, nothing in this Agreement prohibits or prevents the Executive from receiving individual monetary awards or other individual relief by virtue of participating in such federal whistleblower programs.
 
b.           Executive shall not have relinquished his right to commence a Proceeding to challenge whether Executive knowingly and voluntarily waived his rights under ADEA.
 
3.          Executive acknowledges that Executive has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code section 1542, a statute that otherwise prohibits the release of unknown Claims, which provides as follows:
 
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR THE RELEASED PARTY.
 
A-2
Being aware of said code section, Executive agrees to expressly waive any rights Executive may have thereunder, as well as under any other statute or common law principles of similar effect.
 
4.           Executive hereby acknowledges that the Company Group has informed him that he has up to twenty-one (21) days to sign this General Release of Claims and he may knowingly and voluntarily waive that twenty-one (21) day period by signing this General Release of Claims earlier. Executive also understands that he shall have seven (7) days following the date on which he signs this General Release of Claims within which to revoke the release of ADEA claims by providing written notice of his revocation to the Company Group (the “Revocation Period”).
 
5.           Executive acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of California applicable to contracts made and to be performed entirely within such State.
 
6.           Executive acknowledges that he has read this General Release of Claims, that he has been advised that he should consult with an attorney before he executes this General Release of Claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof.
 
7.          This General Release of Claims shall take effect on the eighth day following Executive’s execution of this General Release of Claims unless Executive delivers written revocation(s) to the Company within the aforementioned Revocation Period.
 
 
/s/ Andrew Jackson
  
 
ANDREW JACKSON
   
May 2, 2023



A-3
 EX-101.SCH 3 erna-20230502.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 erna-20230502_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 erna-20230502_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00002.jpg begin 644 image00002.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 02, 2023
Entity File Number 001-11460
Entity Registrant Name Eterna Therapeutics Inc.
Entity Central Index Key 0000748592
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 31-1103425
Entity Address, Address Line One 1035 Cambridge Street
Entity Address, Address Line Two Suite 18A
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 212
Local Phone Number 582-1199
Title of 12(b) Security Common Stock, par value $0.005 per share
Trading Symbol ERNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 brhc20052521_8k_htm.xml IDEA: XBRL DOCUMENT 0000748592 2023-05-02 2023-05-02 false 0000748592 NASDAQ 8-K 2023-05-02 Eterna Therapeutics Inc. DE 001-11460 31-1103425 1035 Cambridge Street Suite 18A Cambridge MA 02141 212 582-1199 false false false false Common Stock, par value $0.005 per share ERNA false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( - SI58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #0,Z56>""(6^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VU1(71S43PI""XHWD(RNQMLFI",M/OVIG&WB^@#"+EDYL\W MWT!Z'83V$9^C#QC)8KJ:W3 FH<.&'8B" $CZ@$ZE.B?&W-SYZ!3E:]Q#4/I# M[1%:SF_ (2FC2,$"K,)*9+(W6NB(BGP\X8U>\>$S#@5F-." #D=*T-0-,+E, M#,=YZ.$"6&"$T:7O IJ56*I_8DL'V"DY)[NFIFFJIZ[D\@X-O#T]OI1U*SLF M4J/&_"I90<> &W:>_-K=W6\?F&QYVU7\.I]MPT7'17O[OKC^\+L(.V_LSOYC MX[.@[.'7OY!?4$L#!!0 ( - SI5:97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MT#.E5G7$8]MC! /1$ !@ !X;"]W;W)K/5^MW+88;I5],+(0E;VF2F9$76YM?^[X)8Y%R!1&90F/@N"2S_E,O/&P_+<3(^'JK")S,1,$U.D*=?;&Y&H MS'C54Q%DC@EX/AG+^I5UW2!A\?O MZO?ES/R*)T8@'+V*HW=:,F9"2^7J*2)0E8UYP95<%95EU%9' MEQ7:)2JX+^U[F0CR5*1+H9N@<(T@H.>4=B\#A.>JXKDZA>=9K*6K;,C9$T\; M$]6B8X7..%G$0O-<%%:&!I[?\ )![%>(_5,0I["@FB>@&HDW\EELFR!QI0#^ MKKK]WH A6(,*:W *%MRDTKG2I4V=D;F%.B-*DZDJ@!>P5=283ES\]@XAI$%M MJL$IC O^1AXBR)]L,74MDD#7(U.>+K6,U@)61$-3PF#K'D!1"\=A%QO5"(M+S@L)]4+[$PRP M;@(4M_&/@%,W@F)1\$%&,7LCM:= M@N(6_T6%D)-9K#*L=;6(]/H,_&,PP(CJQD!Q/U]("VU4K0AE/RU_)G,1%AJR MU8B%*TU5FH(KSJT*7\Y(SC5YY4DAR*?@(@AZ)(=W/Q-SC3X(=>.@N+DO-(]D MMB;S;;I422-M2^MY?L+JGM7]@>%F_IXQ#4G$ M"H2"BRO0U;N]^FY@55[NCY?*PFZ[/(P%!S8W ;Y?*67?!V[+7?UB,OX74$L# M!!0 ( - SI5:?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5; M)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/ M3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O M_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_ M/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R! M6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1< M'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72 M[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<' M')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^ M6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ] M?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1 M/,<0F,7XC&894IT,/O'^8* \^>Q\E MTWLJ.?]74_P$4$L#!!0 ( - SI5:7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://eternatx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - brhc20052521_8k.htm 11 brhc20052521_8k.htm brhc20052521_ex10-1.htm erna-20230502.xsd erna-20230502_lab.xml erna-20230502_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20052521_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "brhc20052521_8k.htm" ] }, "labelLink": { "local": [ "erna-20230502_lab.xml" ] }, "presentationLink": { "local": [ "erna-20230502_pre.xml" ] }, "schema": { "local": [ "erna-20230502.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "erna", "nsuri": "http://eternatx.com/20230502", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052521_8k.htm", "contextRef": "c20230502to20230502", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://eternatx.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052521_8k.htm", "contextRef": "c20230502to20230502", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eternatx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001140361-23-023068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-023068-xbrl.zip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